The Food and Drug Administration issued a Drug Safety Communication on Nov. 9 requiring makers of glucagon-like peptide-1 receptor agonists to add a warning about a rare optic-nerve condition to their labels. The condition, non-arteritic anterior ischemic optic neuropathy, or NAION, causes sudden, painless vision loss in one eye and can leave permanent damage. The warning applies across the class, from Novo Nordisk's Ozempic and Wegovy to Eli Lilly's Mounjaro and Zepbound, along with older GLP-1 medicines and the newer oral product Foundayo.
The FDA's action is a labeling change, not a restriction on the drugs. The medicines remain approved for their existing uses, and the agency did not tell patients to stop taking them. The warning goes in the Warnings and Precautions section of the label, the part clinicians read when they weigh a drug's risks against its benefits. It is the first class-wide statement from the FDA on a question that has been building since a 2024 observational study linked semaglutide to a higher rate of NAION.
The GLP-1 class has become one of the most prescribed in the United States. The drugs are approved for type 2 diabetes and, in some forms, for chronic weight management. They have been shown to reduce blood sugar, drive substantial weight loss, and lower the risk of cardiovascular events in some populations. That is why a rare side effect matters: the larger the treated population, the more absolute cases a small rate produces, and the more patients and clinicians have to weigh the warning against the benefits.
What NAION is
NAION is often described as an eye stroke. It happens when blood flow to the optic nerve head is reduced, damaging the nerve and causing sudden vision loss, usually in one eye. The loss is typically painless. Some patients recover part of their vision, but many do not, and there is no proven treatment that reverses the damage.
The condition is rare. It is also more common in older adults and in people with vascular risk factors such as high blood pressure, diabetes, and sleep apnea. That matters for interpreting the GLP-1 data because the drugs are used in populations that already carry some of those risks. It also makes the warning a matter of informed consent rather than a reason to abandon a class of medicines that has substantial benefits for diabetes and obesity.
The evidence
The FDA's review combined a meta-analysis of 126 randomized trials with more than 134,000 patients, about 78,000 of whom received a GLP-1, and a retrospective real-world study. The meta-analysis found 15 probable NAION events: 10 in patients on a GLP-1, five in patients on placebo, and none in patients on other glucose-lowering drugs. The estimated incidence was 6.4 per 100,000 patient-years with GLP-1s and 3.8 per 100,000 with comparators. For context, the general population rate in adults over 50 has been estimated at roughly 2.3 to 10.2 per 100,000 per year, so the GLP-1 rate sits inside the range that has been reported for the broader population.
The real-world study was mixed. It found no statistically significant increase in NAION risk when GLP-1 users were compared with users of SGLT2 inhibitors, another class of diabetes drugs. It found a higher hazard ratio when GLP-1 users were compared with users of DPP-4 inhibitors. The FDA said it could not identify a mechanism, and animal data were inconclusive. The review was prompted by a 2024 study in JAMA Ophthalmology that found semaglutide users were about four times more likely to develop NAION, a finding that led the European Medicines Agency to classify NAION as a very rare side effect of semaglutide and the UK to add its own labeling language earlier this year.
The numbers are small in absolute terms. Ten events in roughly 78,000 patients is not a common side effect. But NAION can cause permanent vision loss, and the FDA's job is to make sure patients and clinicians know the risk even when it is rare. The warning is the agency's answer to that question.
The distinction between relative and absolute risk is important here. A fourfold relative increase sounds large, but when the baseline rate is a few cases per 100,000 people per year, the absolute increase is small. The FDA's review reflects that tension. The signal is consistent enough to require a warning, but not strong enough to change the approval status of the drugs. The agency's language, "potential increased risk," captures the uncertainty.
What the label now says
The FDA's communication tells patients to report sudden vision loss, visual field defects, or changes in color vision to their clinician right away. It tells clinicians to refer those patients promptly to an ophthalmologist and to consider discontinuing the GLP-1 unless the benefits clearly outweigh the risks. That is a case-by-case judgment, not a blanket instruction to stop.
The warning applies to all GLP-1 receptor agonists, not only the two best-known brands. The class includes semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, and orforglipron, sold under brand names including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, and Foundayo. The FDA said the labels should carry the information in the Warnings and Precautions section, which is where serious but uncommon risks are described.
The GLP-1 class has been through safety reviews before. Regulators have examined pancreatitis, gallbladder disease, gastroparesis, and thyroid tumors, and the labels have been updated as evidence accumulated. The NAION warning follows the same pattern: a rare signal, a review, a label change, and continued monitoring. The difference is that vision loss is sudden and often irreversible, which makes the warning more salient for patients than a gradual metabolic risk.
The guidance matters most for patients who already have vision problems or who have had NAION in the past. For them, the warning may change the conversation with their clinician. For most other patients, the absolute risk remains low, and the benefits of the drugs for diabetes and obesity are well established. The article is not a reason to stop a prescribed medicine without medical advice; it is a reason to know what to report.
The reaction
Novo Nordisk said the data do not establish that semaglutide causes NAION and noted that the condition occurs in people who have never taken a GLP-1. Eli Lilly said the FDA's communication does not cite findings specific to its medicines. Both companies have an interest in defending the class, which is one of the most commercially successful in modern medicine. Analysts at BMO said the warning is unlikely to have a major commercial impact because it does not restrict the drugs' approved uses.
The legal context is less calm. Lawyers have filed about 100 lawsuits against Novo Nordisk over NAION, according to reports, and the FDA's warning may give those cases more material to work with. The companies' statements are a preview of the defense: the association is rare, the evidence is observational, and causation has not been established. The plaintiffs' bar will argue that the warning should have come sooner and that the companies had notice from the 2024 study and the European actions.
The FDA's communication does not resolve the causation question. It says the agency is requiring the warning because of a potential increased risk. That language is carefully chosen. A potential risk is enough to require disclosure, even when the evidence is not strong enough to establish cause and effect.
What patients should know
The practical advice is narrow. Do not stop a GLP-1 on your own. If you notice sudden vision loss, a change in your visual field, or a change in color vision, contact your clinician immediately and ask for an eye examination. If you have a history of NAION or other optic-nerve problems, tell your prescriber before starting or continuing a GLP-1. If you have diabetes or obesity and the medicine is working, the risk-benefit balance is likely unchanged for most patients, but the conversation should include the new warning.
Patients who are doing well on a GLP-1 should not read the warning as a reason to stop. The benefits for diabetes and obesity are real, and the absolute risk of NAION is low. The warning is a prompt to report symptoms and to ask about the risk if there is a history of eye disease. The decision to continue or stop should be made with the prescriber, not on the basis of a headline.
The warning is also a reminder that rare side effects can take years to surface. The GLP-1 class has been studied in tens of thousands of patients, but a condition that affects a few people per 100,000 can be hard to detect in individual trials. The FDA's review combined trials and real-world data for that reason. The result is a small signal that is now on the label, where patients and clinicians can see it.
What to watch
The label updates will roll out over the coming weeks. The European Medicines Agency and the UK regulator may revisit their own language. The lawsuits will continue, and discovery may produce more data on the timing and mechanism of the events. Researchers will look for a biological explanation, including whether the drug class affects blood flow to the optic nerve in a way that is not yet understood.
The commercial impact is likely to be limited. The drugs are approved for diabetes and obesity, and the warning does not change those indications. But the warning could affect prescribing for patients at higher risk, and it could change how clinicians counsel patients who are already concerned about the drugs. The FDA's action is a small addition to a label, but labels are how regulators communicate with the clinic.
A rare risk is still a risk. The label now says so.
Primary sources
- The FDA's Nov. 9, 2026 Drug Safety Communication for the class-wide labeling requirement, the evidence review, and the patient and clinician guidance.
- MedPage Today for the NAION background and the clinical context.
- BioSpace for the scope of the class and the FDA's findings.
- NBC News for the patient guidance and the reaction.
- Euronews for the European context and the prior regulatory actions.
- Bloomberg for the commercial and legal context.